These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 26188491)
1. [Satisfaction of patients with type 2 diabetes mellitus after starting treatment with insulin]. Mancera-Romero J; Carramiñana-Barrera F; Muñoz-González L; Guillén-Álvarez P; Murillo-García D; Sánchez-Pérez MR; Semergen; 2016; 42(5):298-306. PubMed ID: 26188491 [TBL] [Abstract][Full Text] [Related]
2. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus. Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669 [TBL] [Abstract][Full Text] [Related]
3. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Bradley C; Plowright R; Stewart J; Valentine J; Witthaus E Health Qual Life Outcomes; 2007 Oct; 5():57. PubMed ID: 17927832 [TBL] [Abstract][Full Text] [Related]
4. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P; Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116 [TBL] [Abstract][Full Text] [Related]
5. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Peyrot M; Rubin RR; Polonsky WH; Best JH Curr Med Res Opin; 2010 May; 26(5):1047-54. PubMed ID: 20199136 [TBL] [Abstract][Full Text] [Related]
6. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Bradley C; Gilbride CJ Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157 [TBL] [Abstract][Full Text] [Related]
7. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081 [TBL] [Abstract][Full Text] [Related]
8. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403 [TBL] [Abstract][Full Text] [Related]
9. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. Mukherjee AK; Reddy VS; Shah S; Jhingan AK; Ramakrishnan P; Prusty V; Singh NS J Indian Med Assoc; 2009 Jul; 107(7):464-70. PubMed ID: 20112854 [TBL] [Abstract][Full Text] [Related]
10. Treatment satisfaction after commencement of insulin in Type 2 diabetes. Wilson M; Moore MP; Lunt H Diabetes Res Clin Pract; 2004 Dec; 66(3):263-7. PubMed ID: 15536023 [TBL] [Abstract][Full Text] [Related]
11. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
12. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine. Gottesman I; Perron P; Berard L; Stewart J; Basso N; Mettimano K; Elliott T Diabetes Technol Ther; 2012 Oct; 14(10):926-35. PubMed ID: 22775367 [TBL] [Abstract][Full Text] [Related]
14. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471 [TBL] [Abstract][Full Text] [Related]
15. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091 [TBL] [Abstract][Full Text] [Related]
16. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. Polonsky WH; Thompson S; Wei W; Riddle MC; Chaudhari S; Jackson J; Bruno AS Diabetes Obes Metab; 2014 Nov; 16(11):1121-7. PubMed ID: 24919603 [TBL] [Abstract][Full Text] [Related]
17. A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications. Alcubierre N; Rubinat E; Traveset A; Martinez-Alonso M; Hernandez M; Jurjo C; Mauricio D Health Qual Life Outcomes; 2014 Aug; 12():131. PubMed ID: 25138117 [TBL] [Abstract][Full Text] [Related]
18. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes. Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K; J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524 [TBL] [Abstract][Full Text] [Related]
19. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. Genovese S; Tedeschi D Adv Ther; 2013 Feb; 30(2):152-64. PubMed ID: 23430354 [TBL] [Abstract][Full Text] [Related]
20. Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus. Braun A; Sämann A; Kubiak T; Zieschang T; Kloos C; Müller UA; Oster P; Wolf G; Schiel R Patient Educ Couns; 2008 Oct; 73(1):50-9. PubMed ID: 18583087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]